The Pharma Data

JANUARY 10, 2021

Chief Executive Officer of MorphoSys, will present at the 39 th Annual J.P. EST. Live audio of the presentation can be accessed from the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com. The presentation as well as a replay of the webcast will also be available on MorphoSys’ website.

Clinical Development 52

Clinical Development Clinical Trials Clinical Supply Trials 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. During the meeting, the FDA provided encouraging feedback regarding the Phase 3 study of omidubicel pertaining to the pre-specified primary and secondary endpoints. About Omidubicel.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Fierce BioTech

DECEMBER 13, 2023

7 “Make or Break” Factors for Emerging Biopharma Companies This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Licensing 52

Licensing Licensing Science Production 52

Advarra

APRIL 30, 2024

A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. The FDA 1572 Form, CV, financial disclosure form, and medical license should all show consistency regarding the PI’s name. Both the medical licenses and nurse licenses need to be up to date.

Licensing 52

Licensing Licensing Pharmacy FDA 52

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. About AlzeCure Pharma AB (publ).

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

Fierce BioTech

JULY 12, 2023

With so many sources of data, both in-house and licensed, we know it can be hard to sort through it all and analyze what you need to answer your research questions. Real-World Data for Cardiovascular Disease Research These days, top-tier biopharma companies are using real-world data (RWD) to power their cardiovascular disease research.

Disease 52

Disease Research Licensing Licensing 52

FDA Law Blog: Biosimilars

JANUARY 11, 2024

HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico. Two Hyman, Phelps & McNamara, P.C.

Pharmaceuticals 59

Pharmaceuticals Compliance Licensing Licensing 59

The Pharma Data

APRIL 20, 2023

These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified 2.

Treatment 40

Treatment Trials Disease Licensing 40

The Pharma Data

JANUARY 7, 2021

(RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Rakuten Medical’s Chairman and CEO, Hiroshi “Mickey” Mikitani, is scheduled to present virtually at approximately 4:30 a.m.

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

The Pharma Data

DECEMBER 13, 2020

A webcast of the conference call will be available under “News and Presentations” in the Investors & Media section of Relay Therapeutics’ website at [link]. To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

JANUARY 27, 2021

Renowned lymphoma expert Mats Jerkeman, MD, Lund University, will give a presentation on the current treatment landscape, and unmet medical need for patients with relapsed or refractory NHL. .” BioInvent will hold a key opinion leader (KOL) call today, Thursday, January 28 at 5:30 p.m. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

FDA Law Blog: Biosimilars

OCTOBER 14, 2024

Facts Defendants in this case are two licensed physicians and the stem cell clinics they founded. Defendants may also seek en banc review of the decision from the full Ninth Circuit.

Regulations 59

Regulations Treatment FDA Licensing 59

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Translation

MARCH 1, 2024

Brent Fagg currently serves as Virginia Commonwealth University’s Senior Licensing Manager in their TechTransfer and Ventures unit. For instance, when engaging a private engineering firm, costs might be presented as $150/hour for a junior engineer. Our industry partner, proactively shared a comprehensive market strategy report.

Licensing 40

Licensing Licensing Engineering Research 40

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Bactiguard presents updated financial targets for 2025 in connection with the company’s financial report for the third quarter of 2020. We have several interesting licensing projects ongoing and see new, exciting business opportunities. The presentation can be followed at www.bactiguard.com.

Licensing 52

Licensing Licensing Production Marketing 52

FDA Law Blog: Biosimilars

APRIL 25, 2024

This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.

Biosimilars 59

Biosimilars Production FDA Licensing 59

The Pharma Data

JANUARY 14, 2021

Trial results were presented in a late-breaking oral presentation today by UCLA Health’s Zev Wainberg, M.D., The ASCO GI presentation slides are available on the company’s website. The presentation will feature members of the Five Prime management team and Zev A. Wainberg, M.D., About Gastric Cancer and GEJ Cancer.

Trials 52

Trials Treatment Therapies Clinical Trials 52

Perficient: Drug Development

JANUARY 19, 2024

This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.

Compliance 118

Compliance Marketing Licensing Licensing 118

Perficient: Drug Development

FEBRUARY 13, 2024

hotspot” folder is present. ” Conclusion In this article, we’ve explored utilizing OpenJDK to operate the Elasticsearch service, aiming to lower licensing expenses by substituting Oracle JDK. Verify whether the Program Files/Open JDK path has the “jre” folder created or not.

Licensing 52

Licensing Licensing Engineering Production 52

Drug Target Review

APRIL 9, 2024

Our approach to investigate the toxicity driven by nucleolar stress was to induce it with certain arginine-rich peptides, present in patients of ALS, which were known to accumulate at nucleoli and cause this type of stress. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 65

RNA Cell Biology Clinical Development DNA 65

DrugBank

NOVEMBER 7, 2023

The healthcare community can license ASHP data for use in new or existing software, databases, or websites in formats specific to organisational needs. “Partnering with ASHP allows us to address an industry gap that is hindering medical professionals' ability to do their best work,” he remarks.

Pharmacy 84

Pharmacy Community Pharmacies Packaging Pharmaceutical Companies 84

SugarCone Biotech

JUNE 10, 2024

4-1BB enhances the response of activated T-cells to “foreign antigens”: protein fragments derived from infected, diseased or cancerous cells that are presented to T cells by antigen-presenting cells (APC). The NIMBY problem I think the “Cancer Immunity Cycle” as originally presented by Chen and Mellman ( 10.1016/j.immuni.2013.07.012

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

On February 23—the same day that the Agency licensed SIMLANDI (adalimumab-ryvk) Injection , the first interchangeable high-concentration, citrate-free biosimilar to HUMIRA, and that qualifies for First Interchangeable Exclusivity (“FIE”)—FDA denied the Boehringer Petition. mL) in addition to Original Concentration Humira.” mL, 20 mg/0.4

FDA 59

FDA Biosimilars Production Regulations 59

Drug Channels

FEBRUARY 22, 2022

We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars. If you have any questions before purchasing a license to the report, please email me. Download a free report overview for more details. The chart below illustrates the depth and breadth of the 2022 edition. Click to Enlarge].

Pharmacy 96

Pharmacy Specialty Pharmacies Biosimilars Licensing 96

Perficient: Drug Development

JANUARY 18, 2024

To convert and compress the Sitecore license to base 64 string, run the script present in “ConvertTo-CompressedBase64String” method present in the upgrade guide. DATABASE_UPGRADE_TO_VERSION=10.3.1 10.3.1.009452.1448composeltsc2019upgradexp1 folder.

Licensing 52

Licensing Licensing 52

The Pharma Data

NOVEMBER 9, 2021

We delivered strong functional performance, with all divisions showing strong growth instigation,” said Werner Baumann, Chairman of the Board of Management, on Tuesday when presenting the company’s third- quarter results. percent), driven by earnings in North America due to lower product returns and the after damage of license earnings.

Licensing 52

Licensing Licensing Science Production 52

Policy Prescription

MAY 28, 2021

They have been getting it from Canada and are now wondering with this presentation, if that is dangerous.”. and licensed by your state board of pharmacy.” state-licensed board of pharmacy licensed pharmacy.”. state-licensed board of pharmacy licensed pharmacy.”. Emphasis added). over the past 20 years.

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

Drug Target Review

NOVEMBER 22, 2023

We will present some of the data at the end of the study at an international conference next year. We are also developing our own TGF-β pathway inhibitor, IOA-359, which was licensed into iOnctura earlier this year. During her career she has held various licensing and business development positions in pharma and biotech.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

OCTOBER 15, 2020

Data was presented at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 14 through October 17, 2020 in Ottawa, Canada. N axitamab In a poster presentation, Dr. Mora presented data from the Company’s pivotal 201 multicenter study. About Y-mAbs.

Licensing 52

Licensing Licensing Production Treatment 52

Drug Hunter

APRIL 20, 2023

The development of a commercial manufacturing process involving deuterated building blocks is notable given the fact that the non-deuterated species has different pharmacology (lower selectivity due to an active metabolite), presenting a significant CMC challenge that needed to be overcome.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

DrugBank

AUGUST 15, 2024

Intellectual Property Rights  While these partnerships offer potential, they also present challenges related to intellectual property rights and aligning institutional priorities. This highlighted the importance of defining patent scope and licensing terms in such collaborations.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80